Clinical Trial Update: Testing the Addition of an Anti-cancer Drug, Berzosertib, to the Usual Treatment (Radiation Therapy) for Chemotherapy-Resistant Triple-Negative and Estrogen and/or Progesterone Receptor Positive, HER2 Negative Breast Cancer [Phase 1]

View source ↗

Summary

This clinical trial update reports testing the addition of berzosertib to radiation therapy in patients with chemotherapy-resistant triple-negative breast cance…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Breast Cancer
• Estrogen Receptor-positive Breast Cancer
• Progesterone Receptor-positive Breast Cancer
• Triple-negative Breast Cancer

Drugs mentioned

• Berzosertib (berzosertib)

Snippet

Sponsor: National Cancer Institute (NCI) | Conditions: Bilateral Breast Carcinoma, HER2-Negative Breast Carcinoma | Phase 1 | Status: ACTIVE_NOT_RECRUITING